3-CMC (3-Chloromethcathinone): Complete Human Toxicology, Metabolism & Safety Monograph

3-CMC (3-Chloromethcathinone): Complete Human Toxicology, Metabolism & Safety Monograph

Emergency stimulant toxicity: Severe agitation/confusion, seizure, dangerous overheating, chest pain, collapse, severe shortness of breath, very fast/irregular heartbeat, loss of consciousness, or behavior that cannot be kept safe after an unknown stimulant requires urgent medical care.

Quick answer

3-CMC is 3-chloromethcathinone, a chlorinated synthetic cathinone stimulant also known as clophedrone.

Its human evidence base has expanded substantially.

By 2026 it includes:

• a poison-center intoxication series;
• a retrospective 81-case 3-CMC forensic dataset;
• DUID and traffic-accident cases;
• mono-substance case subsets;
• fatalities;
• authentic human metabolism and biomarker studies;
• direct evidence that specimen instability can make the drug disappear from poorly stored samples.

That makes 3-CMC a particularly strong example of why NPS toxicology depends on both pharmacology and laboratory handling.

Identity

History and market evolution

3-CMC appeared in the European NPS market around 2014.

It later became one of the most prominent synthetic cathinones in European seizures, particularly as controls reduced availability of 3-MMC and other stimulants.

A 2026 human biomarker paper reported that 3-CMC represented a very large share of NPS seizures in Europe by 2024.

This market dominance is one reason the human and forensic evidence base has expanded quickly.

Pharmacology

A 2024 U.S. federal scheduling notice summarized 3-CMC as inhibiting reuptake at:

• dopamine transporters;
• serotonin transporters;
• norepinephrine transporters.

The resulting elevation in monoamine signaling produces psychostimulant effects.

Preclinical work confirms:

• locomotor stimulation;
• sensorimotor changes;
• physiologic effects.

No receptor/transporter result should be converted into a human dose equivalence with 3-MMC, 4-CMC or methcathinone.

Human poison-center intoxications

A 2025 Italian study summarized 3-CMC/CMC-related intoxications reported to the national poison-center network from 2014–2025.

All reported patients were male and all cases were nonfatal.

Clinical findings included:

• psychomotor agitation;
• psychosis;
• aggressiveness;
• CNS depression;
• cardiac arrhythmias;
• chest/thoracic pain;
• tachypnea.

This gives 3-CMC a direct human clinical profile rather than one inferred solely from other cathinones.

81-case forensic dataset

A 2026 Polish retrospective study analyzed 81 3-CMC cases from 2015–2025.

Contexts included:

• driving under the influence;
• traffic accidents;
• fatalities.

Importantly, 26 3-CMC cases were mono-substance cases, reducing the polysubstance confounding that dominates much NPS toxicology.

Blood concentration range

3-CMC blood concentrations ranged from below quantification to 2,680 ng/mL.

Fatal-intoxication cases had higher average concentrations than DUID cases.

That group-level pattern is useful.

It still does not create a universal impairment or lethal threshold because individual cases overlap and context matters.

Fatality evidence

3-CMC has appeared in fatal investigations.

2026 virtual-chemsex death

A 62-year-old man was found dead after a virtual chemsex session.

Toxicology found:

• a toxic GHB concentration;
• 3-CMC in a frozen peripheral-blood aliquot;
• 3-CMC metabolites.

The important interpretation is:

3-CMC was analytically confirmed in a fatal polysubstance context, but the case does not establish 3-CMC as the sole cause of death.

The case's greatest value may actually be analytical: it showed how easily 3-CMC can disappear during storage.

Specimen instability: a major forensic issue

In the 2026 chemsex case:

• frozen blood retained detectable 3-CMC and metabolites;
• samples stored at +4°C did not show the same cathinone findings.

Earlier 3-CMC stability work similarly documented substantial degradation over time.

Consequence

A negative delayed sample can reflect:

• degradation;
• storage conditions;
• specimen choice;

rather than true absence of exposure.

This makes pre-analytical handling part of the evidence.

Acute toxicity

Potential severe effects include:

• agitation;
• paranoia/psychosis;
• tachycardia;
• hypertension;
• arrhythmia;
• chest pain;
• tachypnea;
• hyperthermia;
• seizures;
• altered consciousness;
• cardiovascular collapse.

Both stimulant excitation and CNS depression have appeared in human case reports, especially in complex exposures.

Cardiovascular toxicity

Human intoxication data directly include:

• arrhythmias;
• chest pain;
• tachypnea.

The large forensic dataset also places 3-CMC repeatedly in DUID and traffic contexts.

No validated blood concentration predicts a specific cardiovascular event.

Psychiatric toxicity

Documented human effects include:

• psychosis;
• aggression;
• psychomotor agitation.

Risk may be amplified by:

• repeated use;
• sleep deprivation;
• other stimulants;
• psychiatric vulnerability.

Seizures and temperature dysregulation

Seizures have been reported in broader 3-CMC evidence reviewed by WHO/DEA and in stimulant-class toxicology.

Animal work shows temperature and sensorimotor disruption.

Human incidence and dose threshold remain unknown.

Interactions

No controlled 3-CMC interaction trial defines safe combinations.

High-risk contexts include:

• other stimulants;
• serotonergic entactogens;
• MAO inhibitors;
• alcohol/benzodiazepines masking warning signs;
• opioids causing independent respiratory depression;
• GHB/other depressants producing a mixed toxidrome.

Human metabolism

Multiple modern studies now characterize 3-CMC metabolism.

Important pathways include:

• ketoreduction;
• N-demethylation;
• hydroxylation;
• combined N-demethylation + carboxylation;
• oxidative deamination;
• glucuronidation.

Different study systems reveal different metabolite prominence.

That is why authentic human samples remain important.

Authentic human biomarkers

A 2024 study combined:

• human hepatocytes;
• blood;
• urine;
• oral fluid from real cases.

It identified a broader metabolite set than older targeted work.

A 2025 postmortem study found urine particularly informative and identified a keto-reduced metabolite as prominent in authentic specimens.

2026 human route-dependent metabolism

A 2026 naturalistic study in regular psychostimulant users examined urinary/oral-fluid biomarkers after human 3-CMC exposure.

It found that biomarker patterns varied with route.

Examples included:

• greater beta-hydroxy metabolite prominence in one route;
• N-acetylated/carboxylated products in another;
• evidence consistent with N-glucuronidation.

This helps toxicologists interpret exposure without creating a consumer administration comparison.

Pharmacokinetics

Despite strong biomarker work, a complete controlled human PK model remains limited.

There is no universal validated:

• bioavailability;
• time to peak;
• half-life;
• clearance;
• repeated-use accumulation curve.

Metabolite timing and route effects are not a safe-use schedule.

Drug testing

Routine immunoassays

A 2025 study found synthetic cathinones can create both under-detection and misleading cross-reactivity in routine amphetamine/MDMA testing.

3-CMC could trigger an MDMA immunoassay at high experimental concentrations.

That does not make the assay a reliable 3-CMC detector.

Definitive methods

Useful methods include:

• LC-MS/MS;
• LC-HRMS/QTOF;
• parent + metabolite targets;
• carefully handled/frozen specimens when degradation is a concern.

Isomer and analogue differentiation

3-CMC must be distinguished from:

• 2-CMC;
• 4-CMC;
• structural degradation products;
• other chlorinated cathinones.

Mass spectrometry without adequate chromatographic or reference-standard support can be insufficient for confident positional-isomer assignment.

Product identity and stability

Chemical identity can be wrong for two separate reasons:

1. the product was mislabeled;
2. the compound degraded before analysis.

A strong toxicology workflow has to account for both.

A September 2026 study further showed 3-CMC/4-CMC can be unstable under some synthesis/storage conditions, reinforcing the need to interpret delayed seized-material testing carefully.

Tolerance

Repeated stimulant exposure can produce tolerance to subjective effects.

There is no validated 3-CMC-specific tolerance timeline.

Subjective tolerance does not prove protection from:

• arrhythmia;
• hypertension;
• psychosis;
• seizure;
• hyperthermia.

Dependence and stimulant use disorder

3-CMC-specific dependence incidence is not established.

Its monoaminergic stimulant pharmacology creates credible risk of:

• craving;
• compulsive redosing;
• binge use;
• inability to cut down;
• continued use despite harm.

Stimulant withdrawal

After frequent stimulant use, withdrawal can include:

• fatigue;
• hypersomnia or insomnia;
• low mood;
• anhedonia;
• irritability;
• slowed thinking;
• increased appetite;
• craving.

No 3-CMC-specific onset/peak/duration timeline is validated.

Severe depression, suicidality or persistent psychosis warrants clinical care.

Treatment and support

There is no medication approved specifically for 3-CMC use disorder.

The ASAM/AAAP stimulant-use-disorder guideline identifies contingency management as a core evidence-based behavioral intervention, often combined with CBT/community reinforcement.

Acute toxicity is treated according to complications.

U.S. resources include:

• FindTreatment.gov
• SAMHSA National Helpline: 1-800-662-HELP (4357)

Forensic interpretation

Concentration does not equal dose

Blood concentration depends on:

• timing;
• route;
• tolerance;
• metabolism;
• storage;
• specimen;
• co-drugs.

DUID concentration is not a universal impairment cutoff

The 81-case study provides reference distributions, not a validated legal/physiologic threshold.

Fatal concentration is not a universal lethal threshold

Even mono-substance cases cannot be transformed into a dose calculator.

Stability can bias the number downward

Delayed or warm storage can decrease measured parent drug.

Special populations

Controlled 3-CMC safety data remain inadequate for:

• pregnancy/breastfeeding;
• adolescents;
• cardiovascular disease;
• seizure disorders;
• serious psychiatric illness;
• liver/kidney disease.

New animal work suggests possible multiorgan toxicity, but animal findings should not be converted into human incidence estimates.

Legal status

United States

DEA's February 2024 federal notice states that 3-CMC is a positional isomer of methcathinone, a Schedule I substance, and therefore is itself controlled in Schedule I under the CSA.

International

3-CMC was placed in Schedule II of the 1971 Convention on Psychotropic Substances in 2024.

UNODC currently lists its control status as 1971 Convention Schedule II.

Myths and misconceptions

"3-CMC is just chlorinated 3-MMC, so the effects are predictable."
False. Structural similarity does not establish equivalent human potency, metabolism, or toxicity.

"A negative toxicology screen rules it out."
False. Routine assays and sample degradation can both cause misleading results.

"The fatal chemsex case proves 3-CMC alone killed the person."
No. GHB and the full polysubstance context matter.

"A blood level from a DUID case tells exactly how impaired someone was."
No.

"Because many Italian cases were nonfatal, 3-CMC is relatively safe."
No. A separate large forensic dataset includes fatalities and much broader contexts.

Evidence ledger

Related evidence

• 2-MMC
• 3-MMC
• 4-MMC / Mephedrone
• N-Ethylhexedrone
• NEP / N-Ethylpentedrone
• Synthetic cathinones & RC stimulants
• Substance Use, Dependence & Harm Reduction hub

Bottom line

3-CMC is now one of the better-documented newer cathinones in European forensic toxicology.

Its evidence base includes direct poison-center symptoms, 81 forensic cases, mono-substance DUID cases, fatalities, authentic human metabolite research, human biomarker studies, and clear proof that poor sample storage can erase the analytical signal.

That last point is especially important: with 3-CMC, a toxicology result is only as trustworthy as the method and the specimen handling that came before it.